Malaria remains one of the most persistent and complex infectious diseases globally, and despite recent progress, experts warn, adding that the fight is entering a more fragile phase. In a Johns Hopkins briefing held on Wednesday, researchers outlined both encouraging advances and serious emerging threats that infection prevention professionals should be watching closely.
Director of the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health, Dr Jane M. Carlton, emphasised the scale of the ongoing burden. "Malaria is one of the big three global infectious diseases... one of the deadliest and most burdensome in human history," she said.
According to the latest estimates, there are approximately 280 million cases and 600,000 deaths worldwide, with the vast majority occurring in children under 5 years of age. For infection preventionists, this underscores a familiar reality: High-burden infectious diseases continue to disproportionately affect vulnerable populations.
Carlton highlighted several converging threats that are complicating control efforts. "The parasite has become resistant to artemisinin, which is the frontline antimalarial drug," she explained, noting that resistance is now spreading in parts of Africa.
At the same time, mosquito resistance to insecticides is increasing, and even diagnostic tools are being challenged by evolving parasite strains. "Diagnostic tests for malaria are failing due to the spread of mutant malaria parasite strains that cannot be detected," Carlton said.
After decades of research, malaria vaccines are finally being deployed. Dr William Moss, a professor in the departments of Epidemiology and International Health at the Johns Hopkins Bloomberg School of Public Health; deputy director of the Johns Hopkins Malaria Research Institute; and executive director at the School's International Vaccine Access Center, described this milestone as both significant and incomplete. "A safe and effective malaria vaccine has been a holy grail for malaria control for many decades," Moss said.
Two vaccines, RTS,S/AS01 and R21/Matrix-M, are now in use, and while their efficacy is lower than many other childhood vaccines, their impact is meaningful in high-burden settings. "These vaccines are good and can prevent 10s of thousands of deaths each year, but there is a lot of room for improvement," Moss said